Great post as usual narmac and my sentiments entirely. However, my expertise is in the field of brand strategy and brand health. The failure of apabetalone to achieve it's primary endpoint is a very significant failure on top of a previous failure. This might have undermined trust in the science, trust in the clinical trial team and trust in management for RETAIL INVESTORS. It will not, IMHO undermine much of the scientific community until we see the post hocs which I believe will lead to significant positive developments in finding a role for apabetalone in medical treatments at some point. Don also said he believe's the top 70% of investors will not bail just yet.

That being said, what might be the impact on ZCC and/or ZE? IMHO the failure of BoM represents a significant blow to liquidity of ZCC or ZE in the near future. If BoM had achieved it's primary end target there could have been an almost immediate significant value added to Zenith shares and with the combination of the RPS with a high probability of FDA and EDA approval for apabetalone(hence cash flow in 2022 or so) plus some hopeful science on mCRPC (yet to be published and presented at science conferences and only at phase 2 small trial) I believed a NASDAQ could have been viable for liquidity and a source of capital to keep the Zenith ship afloat and funding TNBC + moving to new phase of mCRPC.

As it stands, from the perspective of retail markets providing liquidity and a source of funding at this stage now I do not see that strategy as viable. I do believe that Dart and other big boys will fund the venture. Perhaps Pfizer will make a move, but the past 10 years of history from my perspective tells me they will not move until much more evidence is confirmed. However, if a competitor jumps in that could change the game. Many factors could change things for the positive.

So as I see this sobbering situation at this stage Don can now dodge the liquidity situation for another year or more and the science will continue to develop in, I believe, very interesting and hopeful ways.

Now on a more positive side, if over the coming months the post hocs on apabetalone reveal a role for this drug that gets FDA/EUDA approval the liquidity story could change. My guess, and that is all it is, is that liquidity/NASDAQ is not even on management's radar.

That is my sober perspective at this stage. It will be a long journey IMHO.

However, imagine a scenario in which extreme positive results emerge from BoM on vascular dementia? This could be a game changer. I am, afterall, an optimistic risk taker.

I sincerely hope I am wrong. I'd love positive news at this stage. I have voiced my desire for liquidity to management a few months ago and IR indicated they have passed my thoughts to management.

GLTA

Toinv